This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A Phase III, Randomized, Multi-Centre, Double-Blin...
Clinical trial

A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients with Mild to Moderate Active Ulcerative Colitis (NATRUL-3)

Read time: 1 mins
Last updated:24th Jul 2013
The primary objective of this study is to evaluate the efficacy as defined by the percentage of patients attaining clinical remission following 8 weeks of induction treatment of HMPL-004 given at a dosing level of either 1800 mg/day or 2400 mg/day as compared with placebo in patients with mild to moderate ulcerative colitis that currently have a sub-optimal response to their current regimen of mesalamine.
Category Value
Study start date 2013-07-24

View full details